Drug Type Small molecule drug |
Synonyms Remetinostat (USAN/INN), SHAPE + [3] |
Target |
Mechanism HDAC inhibitors(Histone deacetylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC16H21NO6 |
InChIKeyXDZAHHULFQIBFE-UHFFFAOYSA-N |
CAS Registry946150-57-8 |
Start Date01 Jun 2021 |
Sponsor / Collaborator |
Start Date12 Dec 2019 |
Sponsor / Collaborator Stanford University [+1] |
Start Date01 Oct 2019 |
Sponsor / Collaborator- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10977 | Remetinostat | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Squamous Cell Carcinoma | NDA/BLA | US | 09 Nov 2019 | |
Cutaneous T-Cell Lymphoma | Phase 2 | - | - | |
Squamous Cell Carcinoma | Discovery | US | 09 Nov 2019 | |
Basal Cell Carcinoma | Discovery | US | 07 Jul 2018 | |
Alopecia Areata | Discovery | - | 01 Feb 2017 | |
Plaque psoriasis | Discovery | AU | 01 Sep 2012 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 2 | 25 | (esptdgsudt) = awbdirlkyx jntwapfkvu (ifvxjcrptz ) View more | Positive | 01 Sep 2021 | |||
Phase 2 | 4 | ykibegfzvw(vfwpbnzjje) = vstukwveay ngqfzkdotd (yzsnmtigza, snuapivmvu - bggrihqdbn) View more | - | 20 May 2021 | |||
Phase 2 | 30 | (swtmvwitxc) = vdynczxpif gsmbesxitw (qhympkjtcd, eaobkardew - cywrpkgnsc) View more | - | 05 Jan 2021 | |||
NCT01433731 (ASCO2014) Manual | Phase 1 | 18 | (zrgnnvwjgj) = mdxbmrupfb pznqxeoznv (ejifrdeops ) View more | Positive | 20 May 2014 | ||
placebo | (zrgnnvwjgj) = qxtgszqkur pznqxeoznv (ejifrdeops ) View more |